modelDenosumab_Sutjandra2011_reference

Extends from Pharmacolibrary.Pharmacokinetic.Models.PK_1C.

Information

name:denosumab
ATC code:M05BX04
model:one compartment, IV dosing (PK_1C)
source:Sutjandra L et al. 2011
population:healthy subjects and postmenopausal women with osteopenia or osteoporosis
measured compound:denosumab
review:curated candidate
record page:pharmacolibrary-docs

Parameters as reported in the paper

parametervalueunitmeaning
subcutaneous bioavailability of denosumab64%Fab
k(a)0.00883h-1kel
central volume of distribution2.49L/66 kgV
linear clearance3.06mL/h/66 kgCLnorm

About denosumab

Denosumab is a monoclonal antibody used to treat bone diseases, especially postmenopausal osteoporosis and bone loss linked to cancer. It is widely used and authorised in the European Union, with products covering osteoporosis, bone resorption, bone tumours, and giant cell tumour of bone.

Summary written by glm-5.3-flash from Wikidata Q408283 and the WHO ATC classification and the EMA medicines list; not checked by a person.

Identity, molar mass and metabolites: Denosumab.

References

  1. Sutjandra L et al. (2011). Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clinical pharmacokinetics 50(12):793–807. DOI:10.2165/11594240-000000000-00000 PUBMED:22087866

Parameters

TypeNameDefaultDescription
RealCl_ref6.477563131313132e-09Cl [m3/s]
RealVd_ref0.0026409090909090913Vd [m3]
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.0009Volume of distribution per kg (default 0.9 L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)1bioavailability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)2.7777777777777776e-7clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1e-4administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Info › Therapeutic range (metadata, not used in equations)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008maximal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Info › Substance metadata
Modelica.Units.SI.MolarMassMM (from PK_1C)0molar mass [kg/mol]; 0 = not supplied (molar concentrations are then 0)
Info › Substance metadata (not used in equations)
Pharmacolibrary.Types.DoseLD50 (from PK_1C)0median lethal dose [mg/kg]; 0 = unknown

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)central-compartment elimination half-life = ln(2)*Vd/Cl (1-compartment approximation; NOT the terminal half-life of 2-/3-compartment models)

Revisions

  • 11/2026 generated by pharmacolibrary-dev export.pharmacolibrary_models from Sutjandra_2011: parameters extracted from the paper by the pharmacolibrary-dev pipeline, model built by its engineer, reviewed: curated candidate